Canadian Cancer Trials Group Bulletins


Highlighted Trial -- BRC.4

The current edition of the NCI Bulletin is highlighting BRC.4 -- A Phase III Randomized Study of Pemetrexed Disodium Versus Erlotinib Hydrochloride As Second-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer.

As described in the NCI Bulletin, "In this trial, patients with advanced NSCLC that has recurred or progressed after initial chemotherapy will be tested for EGFR amplification and then randomly assigned to receive either pemetrexed or erlotinib. Doctors want to see if patients with amplified EGFR fare better on erlotinib and whether those without amplified EGFR genes benefit more from pemetrexed. They will also measure the levels of other potential biomarkers of response to treatment, such as mutations in EGFR and in another gene, KRAS, and try to correlate them with response to these drugs."

To view the complete article in the NCI Bulletin, please use this link ...

To view the trial website, please use this link ...